handout 2 b-cell infiltrates. case 6: additional findings b-cells negative with antibodies to: cd5...
TRANSCRIPT
![Page 1: HANDOUT 2 B-CELL INFILTRATES. CASE 6: ADDITIONAL FINDINGS B-cells negative with antibodies to: CD5 CD10 CD23 BCL-6 cyclin D1](https://reader035.vdocument.in/reader035/viewer/2022062516/56649e665503460f94b60ceb/html5/thumbnails/1.jpg)
HANDOUT 2
B-CELL INFILTRATES
![Page 2: HANDOUT 2 B-CELL INFILTRATES. CASE 6: ADDITIONAL FINDINGS B-cells negative with antibodies to: CD5 CD10 CD23 BCL-6 cyclin D1](https://reader035.vdocument.in/reader035/viewer/2022062516/56649e665503460f94b60ceb/html5/thumbnails/2.jpg)
CASE 6: ADDITIONAL FINDINGS
B-cells negative with antibodies to:•CD5•CD10•CD23•BCL-6•cyclin D1
![Page 3: HANDOUT 2 B-CELL INFILTRATES. CASE 6: ADDITIONAL FINDINGS B-cells negative with antibodies to: CD5 CD10 CD23 BCL-6 cyclin D1](https://reader035.vdocument.in/reader035/viewer/2022062516/56649e665503460f94b60ceb/html5/thumbnails/3.jpg)
DIAGNOSIS
PRIMARY CUTANEOUS MARGINAL ZONE LYMPHOMA
Synonyms:•extranodal marginal zone B-cell lymphoma (WHO)•cutaneous immunocytoma (EORTC)•cutaneous follicular hyperplasia with monotypic plasma cells (Schmid et al Am J Surg Pathol 1995; 19: 12)
![Page 4: HANDOUT 2 B-CELL INFILTRATES. CASE 6: ADDITIONAL FINDINGS B-cells negative with antibodies to: CD5 CD10 CD23 BCL-6 cyclin D1](https://reader035.vdocument.in/reader035/viewer/2022062516/56649e665503460f94b60ceb/html5/thumbnails/4.jpg)
CLINICAL
Solitary or multiple tumours
Good response to XRT; CR common
Frequently relapse
Excellent prognosis; 5-year survival >95%
![Page 5: HANDOUT 2 B-CELL INFILTRATES. CASE 6: ADDITIONAL FINDINGS B-cells negative with antibodies to: CD5 CD10 CD23 BCL-6 cyclin D1](https://reader035.vdocument.in/reader035/viewer/2022062516/56649e665503460f94b60ceb/html5/thumbnails/5.jpg)
PCMZL and Borrelia burgdorferi
A proportion of PCMZL associated with B. burgdorferi infection.
Possibly only in some geographic locations;
•Highlands of Scotland +ve•Austria (Graz/Vienna) +ve•USA -ve•Tawain -ve
![Page 6: HANDOUT 2 B-CELL INFILTRATES. CASE 6: ADDITIONAL FINDINGS B-cells negative with antibodies to: CD5 CD10 CD23 BCL-6 cyclin D1](https://reader035.vdocument.in/reader035/viewer/2022062516/56649e665503460f94b60ceb/html5/thumbnails/6.jpg)
PATHOLOGY
Diffuse or periadnexal/perivascular infiltrate
Reactive germinal centres common
Interfollicular/diffuse neoplastic infiltrate•marginal zone cells•small lymphocytes•plasmacytoid/plasma cells
Reactive cells•histiocytes•Eosinphils
![Page 7: HANDOUT 2 B-CELL INFILTRATES. CASE 6: ADDITIONAL FINDINGS B-cells negative with antibodies to: CD5 CD10 CD23 BCL-6 cyclin D1](https://reader035.vdocument.in/reader035/viewer/2022062516/56649e665503460f94b60ceb/html5/thumbnails/7.jpg)
Immunophenotype
•CD20, bcl-2 positive
•CD5, CD10, CD23, bcl-6, cyclinD1 negative
•CD43 +/-
Genetics
•Trisomy 3 in some
•t(11;18) not found (c.f. gastric & bronchial MZL)
![Page 8: HANDOUT 2 B-CELL INFILTRATES. CASE 6: ADDITIONAL FINDINGS B-cells negative with antibodies to: CD5 CD10 CD23 BCL-6 cyclin D1](https://reader035.vdocument.in/reader035/viewer/2022062516/56649e665503460f94b60ceb/html5/thumbnails/8.jpg)
DIFFERENTIAL DIAGNOSIS
1. Other small B-cell lymphomas2. Cutaneous B-cell pseudolymphoma
![Page 9: HANDOUT 2 B-CELL INFILTRATES. CASE 6: ADDITIONAL FINDINGS B-cells negative with antibodies to: CD5 CD10 CD23 BCL-6 cyclin D1](https://reader035.vdocument.in/reader035/viewer/2022062516/56649e665503460f94b60ceb/html5/thumbnails/9.jpg)
FURTHER READING
Rijlaarsdam et al. Histopathology 1993; 23: 117Bailey et al. Am J Surg Pathol 1996; 20: 1011Cerroni et al. Am J Surg Pathol 1997; 21: 1307Goodlad et al. Am J Surg Pathol 2000; 24: 1279Wood et al. J Cutan Pathol 2001; 28: 502 Ye et al. Blood 2003; 102: 1012Chunmei et al. Am J Surg Pathol 2003; 27: 1061
![Page 10: HANDOUT 2 B-CELL INFILTRATES. CASE 6: ADDITIONAL FINDINGS B-cells negative with antibodies to: CD5 CD10 CD23 BCL-6 cyclin D1](https://reader035.vdocument.in/reader035/viewer/2022062516/56649e665503460f94b60ceb/html5/thumbnails/10.jpg)
CASE 7: ADDITIONAL FINDINGS
•Stage IE on staging: bone marrow, CT chest & abdomen
•t(14;18) not found
![Page 11: HANDOUT 2 B-CELL INFILTRATES. CASE 6: ADDITIONAL FINDINGS B-cells negative with antibodies to: CD5 CD10 CD23 BCL-6 cyclin D1](https://reader035.vdocument.in/reader035/viewer/2022062516/56649e665503460f94b60ceb/html5/thumbnails/11.jpg)
DIAGNOSIS
PRIMARY CUTANEOUS FOLLICLE CENTRE CELL LYMPHOMA
•(EORTC: although most cases included in this category display pure diffuse large cell
morphology)
Synonyms:Grade 3 follicular lymphoma & diffuse large B-
cell lymphoma•(WHO: classifying lesion in this way may result
in over-treatment)
![Page 12: HANDOUT 2 B-CELL INFILTRATES. CASE 6: ADDITIONAL FINDINGS B-cells negative with antibodies to: CD5 CD10 CD23 BCL-6 cyclin D1](https://reader035.vdocument.in/reader035/viewer/2022062516/56649e665503460f94b60ceb/html5/thumbnails/12.jpg)
CLINICAL
Solitary plaques, tumours, nodules
Head & neck (scalp)
Respond to local XRT: CR usual
Frequent relapse
Excellent prognosis: 5-year survival ~100%
![Page 13: HANDOUT 2 B-CELL INFILTRATES. CASE 6: ADDITIONAL FINDINGS B-cells negative with antibodies to: CD5 CD10 CD23 BCL-6 cyclin D1](https://reader035.vdocument.in/reader035/viewer/2022062516/56649e665503460f94b60ceb/html5/thumbnails/13.jpg)
PATHOLOGY
As for nodal follicular lymphoma except:
•Higher proportion of grade 3 lesions +/- DLBCL
•Lower incidence of bcl-2 expression (0-60%)
•t(14;18) rarely found
![Page 14: HANDOUT 2 B-CELL INFILTRATES. CASE 6: ADDITIONAL FINDINGS B-cells negative with antibodies to: CD5 CD10 CD23 BCL-6 cyclin D1](https://reader035.vdocument.in/reader035/viewer/2022062516/56649e665503460f94b60ceb/html5/thumbnails/14.jpg)
PRIMARY CUTANEOUS FOLLICULAR LYMPHOMA
High relapse rate but excellent survival
![Page 15: HANDOUT 2 B-CELL INFILTRATES. CASE 6: ADDITIONAL FINDINGS B-cells negative with antibodies to: CD5 CD10 CD23 BCL-6 cyclin D1](https://reader035.vdocument.in/reader035/viewer/2022062516/56649e665503460f94b60ceb/html5/thumbnails/15.jpg)
0
10
20
30
40
50
60
70
80
90
100
% in
co
mp
lete
re
mis
sio
n
Nodal FL PCFL
p<0.01
% in CR
15/15 PCFL in complete remission at end of follow-up period compared with only 49/87 stage I nodal FL (p<0.01: 2). Goodlad et al. Am J Surg Pathol 2002
COMPARISON OF OUTCOME WITH STAGE I NODAL FL:Disease status at end of follow-up
![Page 16: HANDOUT 2 B-CELL INFILTRATES. CASE 6: ADDITIONAL FINDINGS B-cells negative with antibodies to: CD5 CD10 CD23 BCL-6 cyclin D1](https://reader035.vdocument.in/reader035/viewer/2022062516/56649e665503460f94b60ceb/html5/thumbnails/16.jpg)
DIFFERENTIAL DIAGNOSIS
1. Other small B-cell lymphomas
2. Cutaneous B-cell pseudolymphoma
![Page 17: HANDOUT 2 B-CELL INFILTRATES. CASE 6: ADDITIONAL FINDINGS B-cells negative with antibodies to: CD5 CD10 CD23 BCL-6 cyclin D1](https://reader035.vdocument.in/reader035/viewer/2022062516/56649e665503460f94b60ceb/html5/thumbnails/17.jpg)
Garcia et al. Am J Surg Pathol 1986; 10: 454
Yang et al. Am J Surg Pathol 2000; 24: 694
Cerroni et al. Blood 2000: 95; 3922
Franco et al. Am J Surg Pathol 2001; 25: 875
Aguilera et al. Mod Pathol 2001; 14: 828
Goodlad et al. Am J Surg Pathol 2002; 26: 733
FURTHER READING
![Page 18: HANDOUT 2 B-CELL INFILTRATES. CASE 6: ADDITIONAL FINDINGS B-cells negative with antibodies to: CD5 CD10 CD23 BCL-6 cyclin D1](https://reader035.vdocument.in/reader035/viewer/2022062516/56649e665503460f94b60ceb/html5/thumbnails/18.jpg)
CASE 8: ADDITIONAL FINDINGS
Confined to skin on staging
CD5, CD23, cyclin D1 negative
![Page 19: HANDOUT 2 B-CELL INFILTRATES. CASE 6: ADDITIONAL FINDINGS B-cells negative with antibodies to: CD5 CD10 CD23 BCL-6 cyclin D1](https://reader035.vdocument.in/reader035/viewer/2022062516/56649e665503460f94b60ceb/html5/thumbnails/19.jpg)
DIAGNOSIS
LARGE B-CELL LYMPHOMA OF THE LEG(EORTC)
Diffuse large B-cell lymphoma (WHO)
![Page 20: HANDOUT 2 B-CELL INFILTRATES. CASE 6: ADDITIONAL FINDINGS B-cells negative with antibodies to: CD5 CD10 CD23 BCL-6 cyclin D1](https://reader035.vdocument.in/reader035/viewer/2022062516/56649e665503460f94b60ceb/html5/thumbnails/20.jpg)
DIFFUSE LARGE B-CELL LYMPHOMA ARISING PRIMARILY IN THE SKIN
Probably two subtypesCurrently best classified as per EORTC on basis of anatomic location:
1.Primary cutaneous follicle centre cell lymphomaThis includes cases with true follicular
morphology as treatment and outcome are the same
2. Large B-cell lymphoma of the leg
![Page 21: HANDOUT 2 B-CELL INFILTRATES. CASE 6: ADDITIONAL FINDINGS B-cells negative with antibodies to: CD5 CD10 CD23 BCL-6 cyclin D1](https://reader035.vdocument.in/reader035/viewer/2022062516/56649e665503460f94b60ceb/html5/thumbnails/21.jpg)
Primary cutaneous DLBCL on upper body has significantly better prognosis
than primary cutaneous B-cell lymphoma on the leg1.0
0.8
0.6
0.4
0.2
0.0
Cu
mu
lati
ve D
SS
0 50 150100 200 250 300
Months
Upper body (n=17)
Lower body (n=13)
[p=0.0047]
Goodlad et al. Am J Surg Pathol; In press
![Page 22: HANDOUT 2 B-CELL INFILTRATES. CASE 6: ADDITIONAL FINDINGS B-cells negative with antibodies to: CD5 CD10 CD23 BCL-6 cyclin D1](https://reader035.vdocument.in/reader035/viewer/2022062516/56649e665503460f94b60ceb/html5/thumbnails/22.jpg)
COMPARED TO PCFCCL/LBCL ON UPPER BODY, LARGE B-CELL LYMPHOMA OF THE LEG:
•More often female•Older age•More often multiple lesions•Significantly poorer prognosis (5YS <60% c.f. >95%•Significantly higher incidence of bcl-2 expression (~100%)•Less frequent CD10/bcl-6 expression•More often large round cells (centroblasts/immunoblasts) than large cleaved cells
t(14;18) rare at either site
![Page 23: HANDOUT 2 B-CELL INFILTRATES. CASE 6: ADDITIONAL FINDINGS B-cells negative with antibodies to: CD5 CD10 CD23 BCL-6 cyclin D1](https://reader035.vdocument.in/reader035/viewer/2022062516/56649e665503460f94b60ceb/html5/thumbnails/23.jpg)
N.B. standard treatment for nodal DLBCL is aggressive
CTX (anthracycline based); this would be overtreatment
for majority of primary cutaneous DLBCL
irrespective of location
![Page 24: HANDOUT 2 B-CELL INFILTRATES. CASE 6: ADDITIONAL FINDINGS B-cells negative with antibodies to: CD5 CD10 CD23 BCL-6 cyclin D1](https://reader035.vdocument.in/reader035/viewer/2022062516/56649e665503460f94b60ceb/html5/thumbnails/24.jpg)
DIFFERENTIAL DIAGNOSIS
1. CTCL, large cell types, non-epidermotropic
2. T/NK cell lymphomas
![Page 25: HANDOUT 2 B-CELL INFILTRATES. CASE 6: ADDITIONAL FINDINGS B-cells negative with antibodies to: CD5 CD10 CD23 BCL-6 cyclin D1](https://reader035.vdocument.in/reader035/viewer/2022062516/56649e665503460f94b60ceb/html5/thumbnails/25.jpg)
REFERENCES
Vermeer et al. Arch Dermatol 1996
Geelen et al. J Clin Oncol 1998; 16: 2080
Fernandez-Vazquez et al. Am J Surg Pathol 2001; 25: 307
Grange et al. J Clin Oncol 2001; 19: 3602
Fink-Puches et al. Blood 2002; 99: 800
Goodlad et al. Am J Surg Pathol; In press
![Page 26: HANDOUT 2 B-CELL INFILTRATES. CASE 6: ADDITIONAL FINDINGS B-cells negative with antibodies to: CD5 CD10 CD23 BCL-6 cyclin D1](https://reader035.vdocument.in/reader035/viewer/2022062516/56649e665503460f94b60ceb/html5/thumbnails/26.jpg)
CASE 9: ADDITIONAL FINDINGS
Polyclonal kappa/lambda
Polyclonal IgH re-arrangement
![Page 27: HANDOUT 2 B-CELL INFILTRATES. CASE 6: ADDITIONAL FINDINGS B-cells negative with antibodies to: CD5 CD10 CD23 BCL-6 cyclin D1](https://reader035.vdocument.in/reader035/viewer/2022062516/56649e665503460f94b60ceb/html5/thumbnails/27.jpg)
DIAGNOSIS
CUTANEOUS B-CELL PSEUDOLYMPHOMA
Synonyms:lymphocytoma (benigna) cutisSpiegler-Fendt sarcoidB-cutaneous lymphoid hyperplasia
![Page 28: HANDOUT 2 B-CELL INFILTRATES. CASE 6: ADDITIONAL FINDINGS B-cells negative with antibodies to: CD5 CD10 CD23 BCL-6 cyclin D1](https://reader035.vdocument.in/reader035/viewer/2022062516/56649e665503460f94b60ceb/html5/thumbnails/28.jpg)
CUTANEOUS B-CELL PSEUDOLYMPHOMA
Cutaneous infiltrate histologically simulating CBCL
Cliincally may also mimic lymphoma•solitary red nodule/plaque (85-90%)•generalised/multifocal lesions (10-15%)
![Page 29: HANDOUT 2 B-CELL INFILTRATES. CASE 6: ADDITIONAL FINDINGS B-cells negative with antibodies to: CD5 CD10 CD23 BCL-6 cyclin D1](https://reader035.vdocument.in/reader035/viewer/2022062516/56649e665503460f94b60ceb/html5/thumbnails/29.jpg)
AETIOLOGY•Idiopathic
•Borrelia burgdorferi•Tattoo (red)•Injection sites•Acupuncture
•Trauma•Vaccination
•Gold piercing earrings
COMMON THEME IS REACTION TO ANTIGEN
![Page 30: HANDOUT 2 B-CELL INFILTRATES. CASE 6: ADDITIONAL FINDINGS B-cells negative with antibodies to: CD5 CD10 CD23 BCL-6 cyclin D1](https://reader035.vdocument.in/reader035/viewer/2022062516/56649e665503460f94b60ceb/html5/thumbnails/30.jpg)
PATHOLOGY
•Diffuse or nodular infiltrate (Grenz zone)•Reactive polytypic B-cells
Often in nodules +/- germinal centresT-cell rich areas in between
•Prominent vasculature•Macrophages, plasma cells, eosinophils
PRESERVED IMMUNOARCHITECTURE
![Page 31: HANDOUT 2 B-CELL INFILTRATES. CASE 6: ADDITIONAL FINDINGS B-cells negative with antibodies to: CD5 CD10 CD23 BCL-6 cyclin D1](https://reader035.vdocument.in/reader035/viewer/2022062516/56649e665503460f94b60ceb/html5/thumbnails/31.jpg)
B-cell nodules•CD20, CD23
T-cell areas•CD3 +•few B-cells
B-CLH: IMMUNOARCHITECTURE
![Page 32: HANDOUT 2 B-CELL INFILTRATES. CASE 6: ADDITIONAL FINDINGS B-cells negative with antibodies to: CD5 CD10 CD23 BCL-6 cyclin D1](https://reader035.vdocument.in/reader035/viewer/2022062516/56649e665503460f94b60ceb/html5/thumbnails/32.jpg)
DIFFERENTIAL DIAGNOSIS:CUTANEOUS INFILTRATES RICH IN SMALL B-CELLS
1. B-cell pseudolymphoma
2. Marginal zone lymhpoma
3. Follicular lymphoma
4. (Secondary involvement by:• B-CLL• Mantle cell lymphoma)
![Page 33: HANDOUT 2 B-CELL INFILTRATES. CASE 6: ADDITIONAL FINDINGS B-cells negative with antibodies to: CD5 CD10 CD23 BCL-6 cyclin D1](https://reader035.vdocument.in/reader035/viewer/2022062516/56649e665503460f94b60ceb/html5/thumbnails/33.jpg)
NATURE OF LYMPHOID FOLLICLES?
1. REACTIVE FOLLICLES• Found in all three but rare in FL• Appearance as at other sites
Zonation Tingible body macrophages Mitotic figures Well formed mantles Uniform CD10/bcl-6 expression by GCCs Bcl-2 negative
![Page 34: HANDOUT 2 B-CELL INFILTRATES. CASE 6: ADDITIONAL FINDINGS B-cells negative with antibodies to: CD5 CD10 CD23 BCL-6 cyclin D1](https://reader035.vdocument.in/reader035/viewer/2022062516/56649e665503460f94b60ceb/html5/thumbnails/34.jpg)
2. COLONISED FOLLICLES•Typical of MZL•Distinct compartments
Reactive GCC: CD10/bcl-6 +ve, bcl-2 -veNeoplastic MZ cells: CD10/bcl-6 -ve, bcl-2 +ve
3. NEOPLASTIC FOLLICLES•Only seen in FL•Same as in nodal FL
No zonationMonotonous appearanceFew TBMs, MFs (NB grade 3 FL)Absent/poorly formed mantlesUniform CD10/bcl-6 stainingBcl-2 usually +ve (but significant % -ve cases)
![Page 35: HANDOUT 2 B-CELL INFILTRATES. CASE 6: ADDITIONAL FINDINGS B-cells negative with antibodies to: CD5 CD10 CD23 BCL-6 cyclin D1](https://reader035.vdocument.in/reader035/viewer/2022062516/56649e665503460f94b60ceb/html5/thumbnails/35.jpg)
NATURE OF INTERFOLLICULAR INFILTRATE?
1. B-CELL PSEUDOLYMPHOMA• T-cells >> B-cells• NO confluent sheets of B-cells• Polytypic light chain immunohistochemistry• Epidermal changes
e.g. parakeratosis, atrophy, acanthosis, spongiosis
2. MARGINAL ZONE LYMPHOMA•Clusters/sheets of marginal zone cells•>75% B-cells•Light chain restriction•Aberrant CD43 expression
![Page 36: HANDOUT 2 B-CELL INFILTRATES. CASE 6: ADDITIONAL FINDINGS B-cells negative with antibodies to: CD5 CD10 CD23 BCL-6 cyclin D1](https://reader035.vdocument.in/reader035/viewer/2022062516/56649e665503460f94b60ceb/html5/thumbnails/36.jpg)
3. FOLLICULAR LYMPHOMA
•Clusters of CD10/bcl-6+ve B-cells
Useful when bcl-2 –ve
CD10 may be down-regulated
![Page 37: HANDOUT 2 B-CELL INFILTRATES. CASE 6: ADDITIONAL FINDINGS B-cells negative with antibodies to: CD5 CD10 CD23 BCL-6 cyclin D1](https://reader035.vdocument.in/reader035/viewer/2022062516/56649e665503460f94b60ceb/html5/thumbnails/37.jpg)
POLYMERASE CHAIN REACTION
Can be helpful but use limited by:
•Most FL are t(14;18) negative
•False negatives relatively common
•False positive results when very few B-cells
•Some CBCPL are monoclonal
•Some CBCPL progress to overt lymphoma
![Page 38: HANDOUT 2 B-CELL INFILTRATES. CASE 6: ADDITIONAL FINDINGS B-cells negative with antibodies to: CD5 CD10 CD23 BCL-6 cyclin D1](https://reader035.vdocument.in/reader035/viewer/2022062516/56649e665503460f94b60ceb/html5/thumbnails/38.jpg)
THE MOST IMPORTANT DECISION:
SHOULD THE PATIENT BE STAGED?
![Page 39: HANDOUT 2 B-CELL INFILTRATES. CASE 6: ADDITIONAL FINDINGS B-cells negative with antibodies to: CD5 CD10 CD23 BCL-6 cyclin D1](https://reader035.vdocument.in/reader035/viewer/2022062516/56649e665503460f94b60ceb/html5/thumbnails/39.jpg)
FURTHER READING
Ritter et al J Cutan Pathol 1994; 21: 481
Baldassano et al. Am J Surg Pathol 1999; 23: 88
de Leval et al. Am J Surg Pathol 2001; 25: 732
Nihal et al. Hum Pathol 2003; 34: 617